Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

Inclusion Criteria:

Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:

Medically inoperable or unresectable stage II, IIIA, or IIIB disease
Post-resection intrathoracic tumor recurrence
Measurable disease by computed tomography(CT) scan
No evidence of small cell histology
No significant pleural effusion on chest x-ray or malignant pleural effusion on cytology
No metastatic disease
Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1
Absolute granulocyte count ≥ 2,000/mm³
Platelet count ≥ 100,000/mm³
Hemoglobin ≥ 8.0 g/dL
Bilirubin ≤ 1.5 mg/dL
Serum glutamic oxaloacetic transaminase (SGOT) ≤ 1.5 times upper limit of normal (unless abnormality is caused by documented benign disease)
Creatinine ≤ 1.5 mg/dL
Weight loss ≤ 10% within the past 3 months
Forced expiratory volume (FEV) 1 ≥ 1,000 cc
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after completion of study treatment

Exclusion Criteria:

Synchronous (except for nonmelanomatous skin cancer) or prior invasive malignancy, unless disease free for > 3 years
Myocardial infarction within the past 6 months

Symptomatic heart disease, including any of the following:

Angina
Congestive heart failure
Uncontrolled arrhythmia
Active infection or fever ≥ 38.5°C within the past 3 days
Known hypersensitivity to any of the components of oxaliplatin or docetaxel
Prior thoracic or neck radiotherapy
Prior docetaxel or oxaliplatin